Drugs Propranolol may cause vivid dreams and is not usually recommended for people with pre-existing breathing difficulties.Medicines that interact with propranolol may either decrease its effect, affect how long it works for, increase side effects, or have less of an effect when taken with propranolol. Revision date: October 2, 2019.Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. 288154-overview 80 mg/day PO divided q6-8hr initially; may be increased by 20-40 mg/day every 3-4 weeks; not to exceed 160-240 mg/day divided q6-8hrInderal LA: 80 mg/day PO; maintenance: 160-240 mg/dayWithdraw therapy if satisfactory response not seen after 6 weeksIV: 1-3 mg at 1 mg/min initially; repeat q2-5min to total of 5 mgOnce response or maximum dose achieved, do not give additional dose for at least 4 hours10-60 mg PO q6-8hr; 10 mg PO q8hr initially; titrate dose to reduce resting heart rate by 25%40 mg PO q12hr initially; maintenance: 120-320 mg/day PO divided q8-12hrOrphan designation for treatment of malignant glioma (plus etodolac)20-180 mg PO q12hr; adjust to maximum tolerated doseHemangeol: Indicated for treatment of proliferating hemangioma requiring systemic therapyStarting dose: 0.6 mg/kg (0.15 mL/kg) PO BID for 1 week, THEN increase dose to 1.1 mg/kg (0.3 mL/kg) BID; after 2 more weeks, increase to maintenance dose of 1.7 mg/kg (0.4 mL/kg) BID 0.5-1 mg/kg/day PO divided q6-12hr initially; increase gradually every 5-7 days; usual range: 2-4 mg/kg/day PO divided q12hr PO: 0.5-1 mg/kg/day divided q6-8hr; may be increased every 3-7 days; usual range: 2-6 mg/kg/day; not to exceed 16 mg/kg/day or 60 mg/day IV: 0.01-0.1 mg/kg over 10 minutes; repeat q6-8hr PRN; not to exceed 1 mg for infants or 3 mg for childrenPO: 1 mg/kg/day divided q6hr; after 1 week, may be increased by 1 mg/kg/day to maximum of 10-15 mg/kg/day if patient refractory; allow 24 hours between dosing changes IV: 0.01-0.2 mg/kg over 10 minutes; not to exceed 5 mgOrphan designation for treatment of retinopathy of prematurityImmediate-release: 40 mg PO q12hr initially, increased every 3-7 days; maintenance: 80-240 mg PO q8-12hr; not to exceed 640 mg/dayInderal LA: 80 mg/day PO initially; maintenance: 120-160 mg/day; not to exceed 640 mg/dayInnoPran XL: 80 mg/day PO initially; may be increased every 2-3 weeks until response achieved; maintenance: not to exceed 120 mg/day POIV: 1-3 mg at 1 mg/min initially; repeat q2-5min to total of 5 mgOnce response or maximum dose achieved, do not give additional dose for at least 4 hoursAllergic: Hypersensitivity reactions, including anaphylactic/anaphylactoid; agranulocytosis, erythematous rash, fever with sore throatSkin and subcutaneous tissues disorders: Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis, erythema multiforme, urticaria, purpura, dermatitis psoriasiformMay exacerbate ischemic heart disease after abrupt withdrawalHypersensitivity to catecholamines has been observed during withdrawalExacerbation of angina and, in some cases, myocardial infarction occurrence after abrupt discontinuanceWhen discontinuing long-term administration of beta blockers (particularly with ischemic heart disease), gradually reduce dose over 1-2 weeks and carefully monitorIf angina markedly worsens or acute coronary insufficiency develops, reinstate beta-blocker administration promptly, at least temporarily (in addition to other measures appropriate for unstable angina)Warn patients against interruption or discontinuance of beta-blocker therapy without physician adviceBecause coronary artery disease is common and may be unrecognized, slowly discontinue beta-blocker therapy, even in patients treated only for hypertensionSevere sinus bradycardia or 2°/3° heart block (except in patients with functioning artificial pacemaker)Long-term beta blocker therapy should not be routinely discontinued before major surgery; however, the impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anesthesia and surgical proceduresUse caution in bronchospastic disease, cerebrovascular insufficiency, congestive heart failure, diabetes mellitus, hyperthyroidism/thyrotoxicosis, liver disease, renal impairment, peripheral vascular disease, myasthenic conditionsSudden discontinuance can exacerbate angina and lead to myocardial infarctionHypersensitivity reactions, including anaphylactic and anaphylactoid reactions, have been reportedCutaneous reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis, erythema multiforme, and urticaria, have been reportedExacerbation of myopathy and myotonia has been reportedLess effective than thiazide diuretics in black and geriatric patientsMay worsen bradycardia or hypotension; monitor HR and BPAvoid beta blockers without alpha1-adrenergic receptor blocking activity in patients with prinzmetal variant angina; unopposed alpha-1 adrenergic receptors may worsen anginal symptomsMay induce or exacerbate psoriasis; cause and effect not establishedPrevents the response of endogenous catecholamines to correct hypoglycemia and masks the adrenergic warning signs of hypoglycemia, particularly tachycardia, palpitations, and sweating May cause or worsen bradycardia or hypotensionPregnancy category: C; intrauterine growth retardation, small placentas, and congenital abnormalities reported, but no adequate and well-controlled studies conductedLactation: Use is controversial; an insignificant amount is excreted in breast milkA: Generally acceptable.

Propranolol is more likely than some other beta blockers (such as atenolol) to cause vivid or unusual dreams. provider for the most current information.The recipient will receive more details and instructions to access this offer.By clicking send, you acknowledge that you have permission to email the recipient with this information.The recipient will receive more details and instructions to access this offer.By clicking send, you acknowledge that you have permission to email the recipient with this information. Abrupt discontinuation has been associated with exacerbation of angina, and rarely, heart attacks. The American Thyroid Association and American Association of Clinical Endocrinologists recommend beta-blocker therapy for the symptomatic treatment (e.g., tachycardia, muscle weakness, tremor, etc.) https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9yZWZlcmVuY2UubWVkc2NhcGUuY29tL2RydWcvaW5kZXJhbC1pbmRlcmFsLWxhLXByb3ByYW5vbG9sLTM0MjM2NA==